Abstract
Patients with fatty acid oxidation (FAO) defects develop a cardiomyopathy, yet the underlying mechanism is unclear. Using our established working mouse heart model and 13C‐methodology, we have compared the metabolic phenotype of hearts from VLCAD deficient (VLCAD−/−) mice, which is the most common FAO disorder in human, and their control VLCAD+/+ counterparts. The expression of selected metabolic genes was also assessed using qPCR. Unexpectedly, 3 month‐old fed or fasted, or 7 month‐old fed VLCAD−/− mouse hearts displayed values for exogenous long chain FAO that were similar to controls, suggesting a compensatory mechanism, although the partitioning of these FA between oxidation and triglycerides was altered in these hearts. Gene expression profiling data revealed little or no difference in the transcript levels for other long chain FAO enzymes (Acadl and Acad9) in 3 or 7 month‐old VLCAD−/− hearts, but that of hormone sensitive lipase (Hsl) was significantly decreased (p<0.001) at 7 months following fasting. Finally, VLCAD−/− hearts showed additional lipid alterations, namely a 30% (p<0.001) decline in docosahexaenoic acid levels in cardiac phospholipids at 3 and 7 months. Collectively, our data highlight unexpected age‐dependent metabolic alterations in VLCAD deficient mouse hearts, which may contribute to cardiomyopathy development. (Supported by NIH & CIHR)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
